Telomir Pharmaceuticals Surges 147% Amid Promising Telomere Research

Telomir Pharmaceuticals, Inc. Overview

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a pre-clinical–stage biopharmaceutical company headquartered in Miami, Florida. Founded in August 2021, the firm is developing Telomir-1, an oral small molecule intended to regulate metal homeostasis, protect telomere caps, and mitigate oxidative stress, DNA damage, chronic inflammation, and mitochondrial dysfunction, which may contribute to aging and chronic diseases.

Corporate Structure and Leadership

Since its initial public offering on February 8, 2024, Telomir has operated as a publicly traded entity. The company’s executive team includes Erez Aminov (Chairman and Chief Executive Officer) and Dr. Christopher Chapman (Co-founder, Chairman, CEO & CMO). In December 2023, Telomir established a 14-member longevity advisory panel comprising experts from medicine, ethics, law, economics, and public relations. While specific employee counts are not publicly disclosed, Telomir collaborates with external research partners, such as Nagi Biosciences SA, and engages with organizations like the Progeria Foundation to advance its pipeline.

Telomere Therapy by Iván C. Fajardo

Recent Developments and News

• February 8, 2024 – Initial public offering of 1,000,000 shares at $7.00 per share, raising gross proceeds of $7 million. Underwriters retained a 45-day option to purchase up to an additional 150,000 shares.
• April 15, 2024 – Presentation at the National Press Club (Washington, D.C.) by Drs. Chapman and Michael Roizen, providing details on in vitro data showing a 40 percent increase in telomerase activity and measurable telomere extension following Telomir-1 treatment. Preclinical benchmarks included assessments of gait, joint health, and synovial fluid markers in animal studies.
• November 21, 2024 – Publication of in vivo microfluidic studies conducted in collaboration with Nagi Biosciences SA on Caenorhabditis elegans, demonstrating findings such as extended healthy lifespan and enhanced mobility in advanced life stages.
• July 17, 2025 – Form 8-K filing under Item 8.01, indicating material corporate developments; further details are pending public disclosure.
• LinkedIn Coverage – A Longevity.Technology article discussed Telomir-1’s effects on telomere elongation, potential epigenetic impact, and oxidative stress reduction in a Werner syndrome model.

Financial and Strategic Analysis

Telomir’s February 2024 IPO provided an initial capital infusion of $7 million before expenses. As of Q2 2024 (quarter ended June 30), the company reported net losses decreasing from $2.90 million in the prior quarter to $2.18 million, attributed to controlled research and development spending. No revenues have been recognized to date, reflecting its pre-clinical status. Strategically, Telomir focuses on inhibiting IL-17 and activating telomerase, targeting age-related inflammatory conditions, including hemochromatosis and osteoarthritis, as well as recovery post-chemotherapy. Collaborations with Nagi Biosciences and the Progeria Foundation support both in vitro and in vivo research, while preparations for Investigational New Drug (IND) and Advanced IND applications aim to progress Telomir-1 into clinical trials.

Market Position and Industry Context

Telomir-1 is among 83 investigational IL-17–targeted compounds across 95 indications, supported by 111 R&D institutions, 732 registered clinical trials, and 425 related patents (as of April 18, 2024, per Synapse). The anti-aging and chronic disease markets include various telomerase modulators and anti-inflammatory agents; Telomir’s orally administered, stem-cell-focused approach differentiates it from other therapeutic modalities, such as injectable biologics and gene therapy. With its proprietary small-molecule platform, Telomir positions itself within the emerging sector of systemic, orally administered age-reversal therapeutics.

tl;dr

As of July 18, 2025, TELO shares increased by 147.94 percent to $3.0001 on a trading volume of approximately 16 million shares. Investor attention is directed toward upcoming IND and Advanced IND submissions for Telomir-1, alongside ongoing studies involving progeria cell lines and organisms. Anticipated milestones in the second half of 2025 include formal FDA filings, potential expansions of strategic partnerships, and additional data releases from pre-clinical research.